中西医结合治疗高催乳素血症临床研究

《中西医结合治疗高催乳素血症临床研究》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、中西医结合治疗高催乳素血症临床研究中西医结合治疗高催乳素血症临床研究文章编号：1008-6919(2006)10-0091-03中图分类号:R711.77文献标识码：A【摘要】目的：前瞻性研究中西结合治疗高催乳素血症的临床疗效。方法将2004年1月〜2006年2月我院妇科门诊95例高催乳索患者进行随机分组，中西药组56例，采用中西医结合疗法，即漠隐亭加中医辩证治疗；西药组39例，单纯给予漠隐亭治疗，对比分析两组治疗结果。结果中西药组治愈率73.21%，总有效率91.07%,反跳率0.00%,复发率31.37%；西药组治愈率51.28%

2、，总有效率82.05%,反跳率15.63%,复发率68.75%。两组治愈率、总有效率、反跳率和复发率比较，结果分別为P<0.05、P〉0.05、P〈0.05和P<0.Olo结论中西医结合疗法和单纯西药治疗对高催乳索血症的总有效率相近，但中西医结合疗法可提高治愈率，明显减少停药后的复发和反跳。关键词：高催乳素血症：漠隐亭：中西医结合疗法：辩证论治ClinicalstudyonhyperprolactinemiaWithCombinationtreatmentofTCMandWesternMedicineAbstractObjective

3、:ToProspectivelystudytheclinicaleffectsonhyperprolactinemiaWithCombinationtreatmentofTCMandWesternMedicine.Methods95casesdiagnosedhyperprolactinemiaingynaecologydepartmentfromJanuary2004toFebruary2006wererandomlydividedintotwogroups:TCMandwesternmedicinetherapygroup(56c

4、ases),inwhichthepatientsweretreatedbycombinationofTCMandwesternmedicine,i.e.treatmentwithBromocriptine(BRC)andChinesetreatmentdeterminationbasedonsyndromedifferentiation,andwesternmedicinetherapygroup(39cases),inwhichthepatientsweretreatedonlywithBRC・Thetherapeuticeffec

5、tofthetwogroupswascompared・ResultInTCMandwesternmedicinetherapygroupthecuerateis73.21%,thetotaleffectiverateis91.07%,thebreakthroughrateis0.00%andtherecurrencerateis31.37%;whileinwesternmedicinetherapygroupitis51.28%,82.05%,15.63%and6&75%respectively.Comparethecuerate,t

6、hetotaleffectiverate,thebreakthroughrateandtherecurrenceratebetweenthetwogroups,theresultisP<0.05,P>0.05,P<0.05andP<0.01respectively.ConclusionthetotaleffectiverateofthetreatmentcombinationwithTCMandwesternmedicineandthetreatmentonlywithwesternmedicineissimilar,buttreat

7、mentcombinationwithTCMandwesternmedicinecanincreasethecurerate,anddecreasetherecurrencerateandbreakthroughratesignificantly.[KEYWORDS]:hyperprolactinemia,Bromocriptine,CombinationtreatmentofTCMandWesternMedicine,treatmentdeterminationbasedonsyndromedifferentiation高催乳素血症

8、是指多种原因引起血清中催乳素增高的一种下丘脑垂体疾病，以月经过少、闭经、溢乳、无排卵和不孕为特征的综合征。近年来随着放免测定技术的广泛应用，发现高催乳素血症患者有逐年增多的趋势。IIPR在育龄妇女中的发生率为0.4%,占